Table 6. Risk of skeletal fluorosis associated with GSTP1 Rs1695 in subjects, stratified by age.
| ~45 | 46~65 | 66~ | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Case(n) | Control(n) | OR (95% CI)* | Case(n) | Control(n) | OR (95% CI)* | Case(n) | Control(n) | OR (95% CI)* | p | |
| All subjects | 0.292 | |||||||||
| AA | 35 | 244 | 1.0 (ref) | 136 | 352 | 1.0 (ref) | 55 | 85 | 1.0 (ref) | |
| AG+GG | 25 | 128 | 1.410 (0.793, 2.507) | 74 | 211 | 0.844 (0.596, 1.193) | 22 | 47 | 0.671 (0.346, 1.301) | |
| Tibetan | 0.160 | |||||||||
| AA | 15 | 53 | 1.0 (ref) | 51 | 49 | 1.0 (ref) | 25 | 15 | 1.0 (ref) | |
| AG+GG | 5 | 25 | 0.640 (0.200, 2.046) | 15 | 38 | 0.374 (0.180, 0.777) | 12 | 5 | 1.537 (0.427, 5.529) | |
| Kazakh | 0.531 | |||||||||
| AA | 10 | 39 | 1.0 (ref) | 33 | 53 | 1.0 (ref) | 9 | 14 | 1.0 (ref) | |
| AG+GG | 10 | 27 | 1.593 (0.569, 4.458) | 30 | 43 | 1.107 (0.583, 2.103) | 6 | 16 | 0.874 (0.215, 3.549) | |
| Mongolian | 0.119 | |||||||||
| AA | 6 | 65 | 1.0 (ref) | 36 | 63 | 1.0 (ref) | 5 | 9 | 1.0 (ref) | |
| AG+GG | 8 | 26 | 2.980 (0.855, 10.383) | 13 | 25 | 0.981 (0.437, 2.204) | 1 | 4 | 0.281(0.020, 3.953) | |
| Han | 0.176 | |||||||||
| AA | 4 | 64 | 1.0 (ref) | 21 | 151 | 1.0 (ref) | 14 | 40 | 1.0 (ref) | |
| AG+GG | 1 | 32 | 0.791 (0.072, 8.740) | 15 | 66 | 1.467 (0.702, 3.066) | 2 | 5 | 0.342(0.066, 1.771) | |
| Russians | 0.208 | |||||||||
| AA | 0 | 23 | 1.0 (ref) | 6 | 36 | 1.0 (ref) | 2 | 7 | 1.0 (ref) | |
| AG+GG | 1 | 18 | - | 1 | 28 | 0.236 (0.025, 2.212) | 1 | 7 | 0.395 (0.020, 7.866) | |
Adjusted for sex, ethnicity, IF and fluoride exposure. p value testing heterogeneity.